Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis

Appendiceal goblet cell carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

“…Our cohort was relatively young, generally without comorbidities, and the OS experienced by our study cohort is similar to the 18.5 mo OS previously reported by Mahteme and Sugarbaker [11] in 13 patients with appendiceal adenocarcinoid receiving HIPEC. Subgroup analysis based on completeness of cytoreduction also yielded median OS that closely matched theirs [11,12]. McConnell et al [13], who achieved a higher rate of complete cytoreduction, reported a 63.4% 3-y OS.…”

Side-Effects on the Renal function of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

“…We did not find that other factors occurring during CRS and HIPEC surgery, which have also been related to the development of AKI after surgery, such as the PCI (Peritoneal Carcinomatosis Index) 10 , 6 , the duration of surgery 6 , 17 and blood product transfusion 6 , 18 . Despite their potential implications for a more complex surgical course, our findings did not show significant relationships with the occurrence of AKI in our sample.…”

Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin

“…The efficacy of this innovative treatment has also been reported in phase II studies in ovarian cancer (5,6) and in phase III studies in gastric cancer (7,8). These results encourage the clinical application of this aggressive treatment, particularly in conditions such as PC of nongynecologic origin, where the long-term survival is hardly ever seen after SPSC (9,10).…”